GSTO-IN-2 is a novel and potent glutathione S-transferase inhibitor with IC50s of 3.6, 16.3, and 1.4 μM for GSTA2, GSTM1, and GSTP1-1.
Physicochemical Properties
| Molecular Formula | C33H52N2O9 |
| Molecular Weight | 620.773990631104 |
| Exact Mass | 620.367 |
| CAS # | 1202710-57-3 |
| PubChem CID | 45102203 |
| Appearance | White to off-white solid powder |
| LogP | 2.4 |
| Hydrogen Bond Donor Count | 5 |
| Hydrogen Bond Acceptor Count | 10 |
| Rotatable Bond Count | 14 |
| Heavy Atom Count | 44 |
| Complexity | 1110 |
| Defined Atom Stereocenter Count | 11 |
| SMILES | C[C@]12CC[C@]3([H])[C@]4(CC[C@@H](OC(=O)[C@H](CC(=O)O)NC(=O)CC[C@H](N)C(=O)O)C[C@@]4([H])CC[C@@]3([H])[C@]1([H])CC[C@]2([H])[C@H](C)CCC(=O)O)C |
| InChi Key | GEYBDXYFLCDBPT-RHGDXGROSA-N |
| InChi Code | InChI=1S/C33H52N2O9/c1-18(4-11-28(37)38)22-7-8-23-21-6-5-19-16-20(12-14-32(19,2)24(21)13-15-33(22,23)3)44-31(43)26(17-29(39)40)35-27(36)10-9-25(34)30(41)42/h18-26H,4-17,34H2,1-3H3,(H,35,36)(H,37,38)(H,39,40)(H,41,42)/t18-,19-,20-,21+,22-,23+,24+,25+,26+,32+,33-/m1/s1 |
| Chemical Name | (2S)-2-amino-5-[[(2S)-3-carboxy-1-[[(3R,5R,8R,9S,10S,13R,14S,17R)-17-[(2R)-4-carboxybutan-2-yl]-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-3-yl]oxy]-1-oxopropan-2-yl]amino]-5-oxopentanoic acid |
| Synonyms | GSTO-IN-2; GSTO IN2; GSTO IN-2 |
| HS Tariff Code | 2934.99.9001 |
| Storage |
Powder-20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition | Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs) |
Biological Activity
| ln Vitro | In Ref, chemical 3 is GSTO-IN-2. By deactivating the GST isoenzyme, GSTO-IN-2 demonstrated synergy with chemotherapeutic medicines against two cell lines of breast cancer. At 50 μM GSTO-IN-2, the maximum reduction in cisplatin-induced cell viability was noted, reaching up to 640% in comparison with MCF-7 and up to 270% in comparison with MDA-MB-231. The activity-inhibitory action of thiotepa is enhanced by GSTO-IN-2 (25 and 50 μM), which can inhibit MCF-7 by up to 170-320% and MDA-MB-231 by up to 180-270%. [1]. |
| References |
[1]. Lithocholic acid analogues, new and potent alpha-2,3-sialyltransferase inhibitors. Chem Commun (Camb). 2006 Feb 14;(6):629-31. |
Solubility Data
| Solubility (In Vitro) | DMSO : ~100 mg/mL (~161.09 mM) |
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (4.03 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (4.03 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.6109 mL | 8.0545 mL | 16.1090 mL | |
| 5 mM | 0.3222 mL | 1.6109 mL | 3.2218 mL | |
| 10 mM | 0.1611 mL | 0.8055 mL | 1.6109 mL |